Navigation Links
Hard to Treat Diseases (HTDS) To Re Release European TV Segment In N. America For Potential Treatment Of MS
Date:7/28/2009

BELGRADE, SERBIA, July 28 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com, Slavica Bio Chem Division (Slavica) intends to re release a TV feature on the work of the medical team in the area of potential treatment of MS. The TV feature was aired in Europe only, several years ago.

Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer explains: "A few years ago Serbian government TV did a feature about our work, and it took a great public attention. It was about Multiple sclerosis, current therapies, there were also some patients, and our whole team. All of us were talking about our work, our results, our lab was also presented. Also, there were some short movies about MS. It was very good and they repeated it several times on TV." Currently the company is in the process of obtaining translations and writing to the Director of RTS (TV) and intends to post the interview on its corporate web sites www.slavicabiotech.com and www.htdsmedical.com. The company intends to make use of other media ie CD/DVD and similar to distribute the content to other medical professionals, research organizations, and companies in the medical industry to shed additional spotlight on the work of the Slavica Bio Tech team.

In other company news, within the next few weeks Slavica Bio Tech division intends to conduct a web cast only to address the work of Slavica. Dr.Sanja Pekovic, added: "Considering the potential, the exposure, and the spotlight this interview may bring to the company we are grateful and it is our pleasure, to have Professor Rakic (See Biography Link) (http://www.sanu.ac.rs/English/Clanstvo/Biografije/LjubisavRakic.pdf ) accept our invitation to be Slavica's spokesperson for the web cast. He is our Chief scientist and Ribavirin was his idea at the start. Professor Rakic is a well known and highly regarded and respected scientist. He is also the Vice-President of the Serbian Academy of Sciences and Arts in charge for natural sciences."

Company followers are advised that a similar and a second web cast is being planned to feature only the Mellow Hope (HTDS China Subsidiary Vaccine Division) http://www.mellowhope.com/en/main.asp. This second webcast will be chaired by the HTDS CEO, Mr. Terry Yuan.

Dr Pekovic concluded: "We are eager to get the message out to the industry on the work that our team is doing at Slavica. By that we mean not only to our shareholders but to the medical industry as well. We believe that our work is invaluable, that we have made some significant strides, which simply cannot be ignored and we believe that the market is just starting to take notice of our potential. To that end we have hired a liaison contact person, Dr. Ivana Gadjanski. Ivana comes highly qualified to us. She is a PhD. She has recently returned from Germany where she finished her PhD studies and got her PhD diploma, and now is a part of our team. Also, she is an assistant professor at the State University Novi Pazar, she speaks: English -professionally, CAE certificate, grades A, German - upper intermediate level, French - basics and is an enthusiastic young scientist with a lot of fresh and original ideas.

In our team she is responsible for introducing stem cell therapy in our models of EAE/MS and traumatic brain injury. Her duties will also include sending regular updates of our work to our North American office, the head office in China, and having our North American office and our advisors disseminate timely updates to the HTDS followers, shareholders and the medical professionals."

The company intends to provide many updates on the work and HTDS activities on a timely basis.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: corporate@HTDScorporation.com

CONTACT: corporate@HTDScorporation.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. New treatment effective in counteracting cocaine-induced symptoms
3. New treatment boosts muscle function in myasthenia gravis
4. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
5. Free distribution of insecticide-treated mosquito nets can save lives
6. Kenyan malaria success strengthens call for free insecticide-treated nets for all
7. Broad-based group of physicians calls for improvement in stroke treatment
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
10. Non-medicinal treatment touted for pre-schoolers with ADHD
11. Nonmedicinal treatment touted for preschoolers with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: